Phase I Results

Syntopix Group plc 16 August 2007 For immediate release 16 August 2007 SYNTOPIX GROUP PLC ('Syntopix' or 'the Company') PHASE I TRIAL RESULTS IN ACNE Syntopix Group plc (AIM: SYN), the speciality pharmaceutical research and development company focused on dermatological diseases, announces the results of a human use Phase I trial that validated the Company's methodology for determining the potential of compounds as topical treatments for acne, with positive and negative controls performing as expected. The study confirmed the safety and tolerability of all three test treatments in the skin environment. All the test treatments exhibited some antibacterial activity, with this activity sustained throughout the trial in one of the three treatment groups. Further optimisation work will be required before the test treatments can proceed to later stages of clinical development. The Syntopix test treatments were assessed over 14 days in a double-blind, randomised and controlled trial of 22 healthy volunteers. They were SYN 0017 (an antioxidant present in foods and cosmetics), SYN 0401 (an antifungal present in personal healthcare products), and a combination of SYN 0017 and SYN 0016 (an oxidising agent present in pharmaceutical preparations). All three treatment groups produced positive safety and tolerability data with no adverse events being recorded. Additionally, all of the treatments produced a significant reduction in the number of Propionibacterium acnes (P. acnes) after four hours. P. acnes is a bacterium associated with acne and was being used in the trial as a surrogate marker to indicate clinical activity. For one treatment, four of the seven subjects showed a consistent benefit over the two weeks of the study. In addition to further evaluation of these test treatments, Syntopix will continue to assess other compounds from its library of more than 1100 diverse compounds for topical treatments for acne. Stephen Jones, Syntopix' CEO, commented: 'Whilst all the test treatments were shown to be active in the skin environment, further evaluation and optimisation work is required to maximise their efficacy. We will also continue to evaluate other suitable compounds from our extensive library of highly diverse compounds for the topical treatment of acne.' Syntopix confirms that the information required by Rule 26 of the AIM Rules for Companies (February 2007) is available within the Investor Relations section of the Company's website at http://www.syntopix.com/. For further information please contact: Syntopix Group plc 0845 125 9204 Stephen Jones, Chief Executive Officer Rod Adams, Chairman KBC Peel Hunt Ltd 020 7418 8900 Capel Irwin Buchanan Communications 020 7466 5000 Mark Court/Catherine Breen Notes to editors About Syntopix Group plc Syntopix, a group focused on the discovery and development of drugs for the topical treatment of dermatological diseases. The company was founded in 2003 as a spin-out from the University of Leeds by Dr Jon Cove and Dr Anne Eady, two of the leading experts in skin microbiology, with initial funding from The Wellcome Trust. Syntopix' strategy is to seek to reduce the risks and costs of drug discovery and development by discovering novel uses for known compounds. The company concentrates on compounds and combinations of compounds that have a history of safe use in man; and that have well characterised properties, for example antimicrobials and anti-inflammatories. The Group currently has 10 pending UK patent applications. Syntopix is currently concentrating on acne and Staphylococcus aureus infections and has identified a pipeline of lead drug candidates that it intends to take through pre-clinical and, as appropriate, clinical trials. The Group intends to out-license products to commercial partners on obtaining proof of principle and to seek co-development partnerships. The Group is based at the Institute of Pharmaceutical Innovation in Bradford, giving access to the expertise in skin biology, formulation and toxicology at the universities of Bradford and Leeds. Syntopix' shareholders include Techtran Group Limited (a subsidiary of IP Group plc), The Wellcome Trust Limited, University of Leeds Limited, White Rose Technology Limited and Ridings Early Growth Investment Company Limited. Syntopix joined the AIM market of the London Stock Exchange in March 2006. For further information please visit www.syntopix.com. This information is provided by RNS The company news service from the London Stock Exchange

Companies

Gunsynd (GUN)
UK 100

Latest directors dealings